Share
1,545 Posts.
lightbulb Created with Sketch. 207
clock Created with Sketch.
19/03/24
09:15
Share
Originally posted by rusty02:
↑
- income derived from Clarion (some numbers)............... Not until the first qtyly after patents have begin therapy. This could be 2nd quarter. - a cap raise........................................Not at this level of liquidity. I would assume a major push in developments leading into a raising. Next lot of news Near term; *Updated and the RePosa TP2B3 site approvals and accepting patents. *Analytic report and TP2 PSIGAD *Pre IND/FDA feed back on PSIGAD TP2B for the US *Updates on CannQuit N trials *Mr Robert Clark's package updates. Assume that this package will be re-negotiated. *Possibly; 675A interim data. Early H2 Regulatory developments in Europe for the RePosa trials. Regulatory developments in UK for PSIGAD trials. CannQuit O. Bigger TAM than CannQuit N. (Having 4 trials might be a tall order with available COH) Clarion updates and Qtrly. Late H2 Hopefully; Once Analytic PSIGAD report, patent intake with Reposa TP2B3, CannQuit N updates and positive PSI TP2B FDA feedback a new and updated presentation squarely focused on the US market focusing on late stage drug developments and benchmarks. Commencing RePosa TP2B3 will be a huge milestone for Incannex bring IHL-42X our first drug/compound asset squarely into late stage development. A big tick for the US investors. GL @Slyau90
Expand
Possibly* and hopefully* the news you listed will not create another pump and dump event like the previous Psi Gad reading and many other news that seemed to be positive. I still believe cap raise will be on the table even at the current level or prior to another pump and dump event though. That's just my personal assumption, simply because the cost of redomicile should show in the March Q as well as the operating cost in Clarion. GL@rusty02